SEC61A1 and acute myeloid leukemia: The results denoted that high SEC61A1 expression predicts unfavorable prognosis in overall survival in AML (SEC61A1high vs SEC61A1low AML cohort, GSE22778, P = 0.0198; GSE12417, P = 0.0177; TCGA [excluding AML-M3], P = 0.0025; TCGA CN-AML, P = 0.0038) (Figure 1c–f).